Compare MTW & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | ABUS |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 749.4M | 836.0M |
| IPO Year | 1994 | 2008 |
| Metric | MTW | ABUS |
|---|---|---|
| Price | $24.66 | $3.74 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | 371.1K | ★ 2.3M |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | 0.52 | ★ 0.84 |
| Revenue | ★ $2,240,900,000.00 | $14,083,000.00 |
| Revenue This Year | $6.39 | $1,208.75 |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $42.98 | ★ $4.35 |
| Revenue Growth | 2.89 | ★ 128.21 |
| 52 Week Low | $10.29 | $3.50 |
| 52 Week High | $25.22 | $5.45 |
| Indicator | MTW | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 60.65 | 32.13 |
| Support Level | $21.09 | $3.50 |
| Resistance Level | N/A | $4.53 |
| Average True Range (ATR) | 1.30 | 0.18 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 76.48 | 15.82 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.